<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55382">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01974232</url>
  </required_header>
  <id_info>
    <org_study_id>1310014390</org_study_id>
    <nct_id>NCT01974232</nct_id>
  </id_info>
  <brief_title>A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag Froom 2009-2013</brief_title>
  <official_title>A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag Froom 2009-2013</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children’s Hospital of Orange County</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective analysis of children (≤21years old) who received clinical treatment
      with either Romiplostim or Eltrombopag at 2 medical centers from 2009-2013.  The children
      included in this study were from Weill Medical College of Cornell University, New York, NY
      and Children's Hospital Orange County, Orange, CA
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Platelet count greater than or = to 50,000</measure>
    <time_frame>on two consectutive weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>An increase in platelets greater than or = to 20,000 over baseline.</measure>
    <time_frame>On two consecutive weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Persentage of weeks with platelet counts greater than or = to 50,000 independant of rescue therapy.</measure>
    <time_frame>For Rescue therapy is defined as receiving IVIG increased dose steroids or platelet transfusions .  When given this resulted in exclusion of platelet counts for  2 full weeks after iniciation of rescue therapy ..</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">33</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Romiplostin group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Eltrombopag group</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients eligible for this study included both males and females ≤ 21 years old (actual
        range 19 months - 19 years) with persistent/chronic ITP lasting &gt;6 months and were
        diagnosed according to the clinical practice guidelines from the American Society of
        Hematology.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. All patients in this study had received prior treatments before the start of TPO
        treatment including corticosteroids, IVIG, IV anti-D, and/or Rituximab.

        Exclusion Criteria:

        1. Children who do not have ITP
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Bussel, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 25, 2013</lastchanged_date>
  <firstreceived_date>October 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ITP,TPO agents, Children, Romiplostin and Eltrombopag</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
